Jarod Rutledge
1,159 posts
Jarod Rutledge
@JarodRutledge1
Scientific omnivore. longevity x neuro x AI builder @ Starbloom Capital. Stanford PhD & EMBL alumn. health and life for all.
- Want to learn about modern tools for quantifying aging? Check out this review I wrote for @NatureRevGenet with @wysscoray and @hammy_oh! nature.com/articles/s4157…
- If you haven't seen my co-first author Hamilton's excellent tweetorial on our paper using blood to measure the aging of different organs in the body, check it out!I am thrilled to present our new study out in @Nature where we measure aging at organ-level resolution in living people with large-scale plasma proteomics + ML! From @wysscoray lab, co-led with former grad student @JarodRutledge1 1/12
- Replying to @katclone and @KKajderowiczThe real question is why does everyone grow cells at 20% O2 which is NOT physiological and likely has metabolic effects that impact translatability of results...
- Replying to @JarodRutledge1You can check out the full paper here! We made it open access so everyone can use it.
- Such a bad take 😮💨 DNA tech literally outpacing Moore's law for decades. we solved gene editing in living people decades before anyone thought possible. in my field we are reversing aging in mice 🤯 By what metric do we lag? Number of governments destabilized maybe?No wonder biotech lags behind software tech Biotech people have PhDs who prefer fancy over actual solutions Software can’t take over biotech soon enough
- Replying to @JarodRutledge1Use 1: better disease stratification will improve clinical trials, enabling cheaper and more effective medicines. One of our key findings is that organ aging is distinct from the ways scientists usually measure disease risk. An example we show is Alzheimer’s disease (AD) 3/10.
- Replying to @JarodRutledge1First, if you haven’t seen the excellent tweetorial from @hammy_oh on some of the basics of the methods and findings, you should check that out too: x.com/hammy_oh/statu…. 2/10I am thrilled to present our new study out in @Nature where we measure aging at organ-level resolution in living people with large-scale plasma proteomics + ML! From @wysscoray lab, co-led with former grad student @JarodRutledge1 1/12
- Replying to @JarodRutledge1Use 3: Personalized preventative medicine. Now we have a toolkit to tell you and your doctors if what you are doing is working for your body. We can start to figure out how to personalize your diet, exercise, and medications to keep all of your organs healthier for longer. 10/10
- First in a series of papers I've planned on Parkinsons disease. There are major gaps in our ability to monitor the underlying disease process. I hope our work moves the needle towards better treatments.Pre-print alert! Exciting study from @JarodRutledge1 discovering novel biomarkers in people with #Parkinsons #PD Aromatic L-Amino Acid Decarboxylase is a novel fluid biomarker of Parkinson's disease medrxiv.org/content/10.110…
- Replying to @JarodRutledge1Use 2: repurpose drugs to fight aging. Our method gives us 2 new strategies to find anti-aging drugs. 1, target proteins from our models; and 2, use the models to find drugs that reverse or slow organ aging. One of the heart aging proteins our model discovered, MYL7, is the 6/10
- Replying to @JarodRutledge1we get from these protein-centric aging models, which we don’t get from other aging clocks based on methylation, etc. We don’t know if this specific target will work, but there are dozens that came out of this analysis and you can see if your favorite protein is one of them! 8/10
- Replying to @JarodRutledge1Some people with AD go downhill fast while others survive for decades, and we don’t understand why. Predicting which patients will decline fast is important for patient care and for developing drugs. AD clinical trials take years and cost hundreds of millions of dollars, so 4/10
- Replying to @JarodRutledge1picking the fastest declining patients is important. This problem is what killed Biogen's first phase 3 aducanimab trial in AD. We show that brain aging works synergistically with the other best predictor of fast decline, plasma pTau181, to identify fast declining patients. 5/10
